Pielotax

Kidney bioregulator

Pielotax is a kidney peptide complex, sold both as an injection and as capsules. It is the one compound in this catalog where the missing pharmacokinetics is least missing — the kidney is the organ whose handling of a small peptide is predictable from first principles, and that prediction cuts against the product as often as it cuts for it. This page does that reasoning out loud, states the trial count, and names the two tests that would settle the question.

What Pielotax actually is — and why that changes the mechanism

Pielotax is a kidney peptide complex. Before anything else, hold the phrase peptide complex up to the light, because it is doing more work on the label than it can carry.

What a complex does not tell you, in numbers. There are 20 protein-forming amino acids, so a chain of 2 residues has 20 × 20 = 400 possible identities. Extend it and the count runs 20³ = 8,000 tripeptides, 20⁴ = 160,000 tetrapeptides and 20⁵ = 3,200,000 pentapeptides — 3,368,400 distinct molecules of 5 residues or fewer, before anything longer is counted. A label reading 'peptide complex' has excluded none of them. It is not a composition; it is a statement that the composition was never determined, and every mechanism sentence written downstream of that phrase — including every claim about transcription on every vendor page for this product — is a sentence about an unknown.

Now the part that is specific to the kidney, and it is the reason this page is more interesting than its neighbors. For every other organ in this catalog you have to argue that a peptide reaches the target. For the kidney you do not, because the kidney is where small molecules in the blood go. A tetrapeptide weighs on the order of 400-600 Da; albumin, the protein the glomerular filtration barrier exists to retain, is hundreds of times heavier, so a peptide that size is filtered essentially freely. The proximal tubule then reabsorbs and degrades what it filters, using brush-border peptidases and — per the 2022 transport review cited below — PEPT2, the high-affinity member of the same proton-coupled oligopeptide transporter family as the intestinal PEPT1.

And that argument cuts both ways, which is the honest part. The kidney therefore sees a higher local concentration of any injected short peptide than any other tissue — the strongest tissue-specificity argument available to anything in this class, and no vendor makes it. It is also the tissue best equipped to take that peptide apart, because hydrolyzing filtered peptide back to amino acids is the proximal tubule's ordinary job and its brush-border aminopeptidases are there to do it. Delivery to the kidney is close to free. Survival at the kidney is the unsolved half, and the 2022 review's own substrate range for PEPT2 is di- and tripeptides — 2 and 3 residues — not complexes of unstated chain length.

What the primary literature on Pielotax actually says

Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081

The transport review, and the kidney is where it is most directly relevant: PEPT2 is the high-affinity member of the same proton-coupled oligopeptide transporter family, and it sits on the apical membrane of the renal proximal tubule. The review's own description of the substrate range is 'basically all di- and tripeptides'. So the kidney has a named peptide-uptake route that most target organs in this catalog do not — and it is still a route for two- and three-residue molecules, not for an unspecified complex.

Systematic search for structural motifs of peptide binding to double-stranded DNA
Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M · Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715

The systematic docking screen — 108,800 peptide-DNA complexes, with a score of about -32 used as the threshold for calling a peptide a binder. Cited here for its coverage rather than its result: the screen is over defined short peptides, and no kidney-derived preparation and no peptide identified from renal tissue appears in it. The computational half of the class argument has never been run on this product's contents, because nobody has published what they are.

The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709

Independent calibration — 24 randomized trials and 2,245 participants across three animal-derived preparations, graded by a group with no stake in them, who concluded that risk of bias was moderate to high and certainty of evidence low to very low. None of those 24 trials had a renal endpoint and none of them studied this product. It is here to show what happens to this class when an outsider grades it.

What is not here. Nothing is indexed under the trade name Pielotax. No renal endpoint has been published for any kidney-derived peptide preparation in this family, in any species. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.

Why the Pielotax evidence is weak — and what it still showed

Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.

Specific to Pielotax. The specific weakness here is that the endpoint the product is sold for is not measured by anything a reader can order. Renal functional reserve — the capacity to raise filtration above baseline under load — is a research measurement requiring a protein or amino-acid challenge and serial clearances. It is not on a comprehensive metabolic panel and it is not on any panel this site sells. So the claim is pitched at a quantity almost nobody will ever measure, while the quantity people do measure, creatinine-based eGFR, is the one most likely to move for reasons that have nothing to do with the kidney.

What the data supports, stated as a count: 0. Zero trials, zero animal studies and zero mechanism papers are indexed under the name Pielotax, and zero renal endpoints have been published for any kidney-derived peptide preparation in this family. That search ran through Europe PMC, PubMed and Google Scholar on 2 September 2026 under the trade name and under the tissue name, and it is stated as a number because 'limited evidence' is not a finding and 0 is.

What the citations below are doing on the page, then. Two of the three are cited for what they exclude. The 2019 docking screen covers 108,800 peptide-DNA complexes at a binder threshold of about −32, and contains no kidney preparation and no peptide identified from renal tissue. The 2021 independent systematic review pooled 24 randomized trials over 2,245 participants and contains 0 renal endpoints, grading risk of bias moderate to high and certainty of evidence low to very low. The 2022 transport review is the only one carrying an argument onto this page, and what it carries is a constraint rather than a support: PEPT2 is real, it is renal, and it moves peptides of 2 and 3 residues.

The epistemic position, precisely. This is not a compound whose trial failed, and it is not a compound whose mechanism was refuted — both of those would require work that was never done. The strongest thing that can be said for it is a structural argument about glomerular filtration that nobody has tested in 0 published experiments; the strongest thing against it is that the argument would have been cheap to test for decades, because measuring creatinine clearance in an animal is a 1970s-vintage technique.

What is actually measured, and what is not. Measured: nothing, for this preparation, in any species. Measured elsewhere and relevant: PEPT2 is a real renal transporter with a substrate range of di- and tripeptides, and the docking screen behind the class mechanism covers 108,800 peptide-DNA complexes, none of them from kidney tissue. Not measured, for this product: its composition, plasma half-life, oral bioavailability, tubular uptake, and any renal functional endpoint in any animal or human. The number of published trials is 0.

Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.

Pielotax pharmacokinetics — how much of it actually gets in

Why there is no half-life here, and what replaces it. A half-life describes the clearance of one compound. This is a mixture, so it has as many clearance curves as it has components and no single figure could be correct for it. The quick-facts line on this card reads about 15-30 min, which is a plausible number for a small peptide in serum and is traceable to no published measurement of this preparation in any species.

What can be reasoned instead, and for once it is a lot. Injected subcutaneously, short peptides meet serum aminopeptidases and are cut from the termini within minutes. In most of this catalog that ends the reasoning. Here it does not, because the target organ is downstream of the filter: what survives the first pass through plasma is filtered at the glomerulus and concentrated in tubular fluid, which is the one route in this class where the drug arrives at its target by the body's own design rather than by hope. The counterweight is that the proximal tubule's brush-border peptidases exist to hydrolyze exactly that filtered load, so the same anatomy that delivers it degrades it.

The oral form is a different product in everything but the label. A swallowed peptide faces gastric acid, pancreatic proteases and the gut wall before it reaches the portal circulation and hepatic first-pass extraction. Oral bioavailability has never been measured for this preparation, or for any preparation in this family, in 0 published studies. An injection is 100% bioavailable by definition, so the two routes cannot be assumed to deliver comparable exposure — and this product is sold in both as though they were interchangeable.

The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 29x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.

What would have to be true for Pielotax to work

The chain, step by step, with the status of each step marked. (1) The complex would have to contain short peptides — not published for this product, in 0 papers. (2) Enough would have to survive injection to be filtered — plausible on general peptide chemistry, where clearance from plasma runs in minutes, and never measured here. (3) They would have to be taken up by tubular cells rather than hydrolyzed at the brush border — PEPT2 exists and is renal, which is the one step with a named transporter behind it, and no uptake of this preparation has been observed. (4) Uptake would have to change transcription in those cells — never observed in renal tissue for any compound in this class. (5) That change would have to move a measurable filtration parameter — never attempted in any species, in 0 studies.

Step 3 is the only one with anything behind it. Steps 4 and 5 are the ones a reader could contribute to for the price of 2 blood draws taken 8-12 weeks apart, which is unusual for this cohort: the kidney has a cheap, standardized functional readout and most targets here do not.

1. Prediction 1 — Cystatin C with eGFR. should be flat, and it is the honest test because it is not moved by muscle mass, diet or creatine, before, and 8-12 weeks after a course. This is the prediction that separates a renal effect from an artifact. Cystatin C runs 0.62-1.15 mg/L in men and 0.55-1.05 in women, and it is produced at a constant rate by all nucleated cells. If a course moves cystatin C-based eGFR and does not move creatinine, something happened to filtration. If it moves creatinine alone, something happened to muscle.
2. Prediction 2 — Comprehensive Metabolic Panel (CMP). creatinine and eGFR should be read against cystatin C, not on their own, before, and at 3 months. The CMP is the panel almost everyone actually has. Its eGFR is calculated from creatinine, which rises with lean mass and with creatine supplementation in people whose kidneys are entirely normal. Reading a small eGFR change on a CMP as evidence that a peptide worked is the single most likely error a reader of this page will make.
3. Prediction 3 — Urinalysis, Routine. should stay negative for protein and blood, before, and at 3 months. Albuminuria is the earliest signal of glomerular injury and it is a cheap dipstick. A product proposed to support renal tissue that coincides with new protein in the urine has falsified itself in the most direct way available, and no other test on this list would catch it as early.
4. Prediction 4 — Uric Acid. worth a baseline, since 3.4-7.0 mg/dL is the reference band and the kidney clears it, before starting. Uric acid is the end product of purine metabolism and is cleared renally, so it is a second, independent read on excretory function that does not depend on the same equation as eGFR.

Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Pielotax did to it — and that difference is the entire point of testing.

Pielotax versus the alternatives

Pielotax versus Cerluten, its nearest neighbor by construction: both are organ peptide complexes with 0 studies indexed under their trade names, so neither wins on evidence. The kidney version has the better mechanistic story by some distance — renal delivery is filtration rather than a leap of faith — while the central-nervous-system version has to cross the blood-brain barrier, which nothing in this class has been shown to do in any published experiment. Better story, same zero.

And against what actually preserves kidney function, which is the paragraph that matters. The two interventions with real evidence are blood-pressure control and glucose control; both are cheap, both are measurable, and both are boring. Beyond them the highest-yield action for most readers of this page is a single test rather than any product. Creatinine-based eGFR routinely flags muscular people and creatine users as having reduced filtration when their kidneys are normal, because creatinine is a product of muscle metabolism. Cystatin C is produced at a constant rate by all nucleated cells, runs 0.62-1.15 mg/L in men and 0.55-1.05 mg/L in women, and is not moved by muscle mass, diet or creatine — so it sees through the confound entirely. Buying an unstudied peptide to chase a number that was never abnormal is the specific failure mode this product invites.

What you are actually buying when you buy Pielotax

Pielotax is an extract, not a molecule. A certificate of analysis can establish sterility, endotoxin load, total protein and the absence of named contaminants. It cannot establish identity, because there is no structure to identify — the product is defined by its process, not by a formula, and there is no mass to check it against the way there is for a 4-residue synthetic. Two vials with clean certificates can legitimately contain different mixtures, and no laboratory test resolves that.

The dual route makes it worse here, not better. This is sold as an injection and as capsules, described as the same preparation. For a defined molecule that claim is checkable in one mass-spectrometry run. For an extract there is nothing to compare, so 'the same preparation, two routes' is an assertion about two manufacturing streams that no assay in this market can test. Ask for sterility and endotoxin on the injectable, because those are real answers to real questions, and note what neither certificate addresses: the injection is 100% bioavailable by definition and the capsule's absorbed fraction has never been measured.

This one is sold in two routes, and a certificate of analysis answers a different question for each. For the injection a CoA can establish sterility and endotoxin, which matter. For the capsules it describes what is in the capsule and says nothing about what leaves the gut. Neither version can establish identity, because an extract has no structure to identify.

Where to get Pielotax

The evidence for Pielotax

Graded by what exists behind each claim.

Human clinical evidence

• The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.

📊 Correlative data

• Sold for kidney support and renal functional reserve. Almost no practical record exists outside the Russian material.
• Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.

🧪 Theoretical / extrapolated

• A kidney-derived peptide preparation proposed to support renal cell gene expression. Renal functional reserve does decline predictably with age, so the target is real.
• Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
• Kidney is the one tissue in this series where the evidence gap is a safety gap too. eGFR is a cheap, routine, objective measurement, and the kidney is also the organ most likely to be harmed by an unstudied compound that concentrates there.

What that tier rests on here. The tier above is class inference with a renal label attached. Nothing is indexed under the trade name Pielotax and no renal endpoint has been published for any kidney-derived peptide preparation in this family. The one citation that carries an argument here, the transport review, constrains the claim rather than supporting it.

What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

Cell, rodent, human — and where it stops

The kidney is the one organ in this catalog where a peptide's fate is genuinely predictable, and that cuts against the product. Anything under about 500 Da with no plasma protein binding is filtered essentially completely at the glomerulus. A short peptide reaching the circulation does not linger; it goes to urine, and on the way it meets the brush-border peptidases of the proximal tubule, which exist specifically to dismantle filtered peptides into amino acids for reabsorption. The kidney is not a passive target here. It is the organ most specialized at destroying this class of molecule.

The nearest real result is about a defined tripeptide, not this product. Zamorskii 2017 reports a nephroprotective effect of the EDL peptide in acute kidney injury of different origins, in animals of different ages. That is a hard endpoint in the right organ — and EDL is a synthetic tripeptide with a formula and a mass, not a kidney extract. Citing it for Pielotax without saying so is precisely the move that makes this market untrustworthy.

Class-level, and no further. Khavinson 2023 is docking without measured transport; Khavinson 2021 is the gene-expression review; Ryzhak 2015 surveyed seven calf tissues in organotypic culture and kidney was not one of them. So this tissue does not even have the cell-culture result the better-served organs in this catalog have.

Where it stops. A PubTator3 search on 6 September 2026 returned no indexed record under this trade name, in any language, and no human renal endpoint for any product in this family.

What nobody has tested yet

This is the easiest pharmacokinetic study in the entire class. If the compound is filtered, it is in urine. A timed urine collection and a mass spectrometer would say whether an oral dose ever reaches the circulation intact — no radiolabel, no biopsy, no animal. Of the twenty-six products in this cohort, this is the one whose absorption question could be answered fastest, and it has never been asked.

The endpoints are already on every panel. Creatinine and cystatin C give two independent estimates of glomerular filtration; urine albumin-to-creatinine ratio detects early glomerular damage at a few dollars a test. A kidney product with no published value for any of the three has never been measured against the organ it names.

Extrapolation, labeled as such. Because filtration concentrates a small peptide in the tubular lumen, the tissue exposure at the proximal tubule could be far higher than the plasma concentration suggests — which is the strongest theoretical argument any product in this catalog has for reaching its target tissue. It also means any toxicity would land there first. Neither the benefit nor the risk version of that prediction has been examined, and both would show up in the same urine test.

Sources read for this page

• Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VKh. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis. Bulletin of Experimental Biology and Medicine 2017;163(3):389–393 · PMID 28744634
• Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
• Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
• Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
• Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619

Pielotax — safety, predicted from mechanism

Pielotax — safety specifics for this compound

Pielotax — interference & stacking

Pielotax — what interferes with this one specifically

Bloodwork to run alongside Pielotax

Baseline first, then again at 8–12 weeks.

The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.

Check results you already have → · All 103 markers A–Z

Pielotax — frequently asked questions

References & further reading

1. Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M — Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
2. Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M — Systematic search for structural motifs of peptide binding to double-stranded DNA · Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
3. Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709

Pielotax inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Pielotax is used for

Pielotax appears under 1 goal in the goal router.

Related Longevity & Bioregulators compounds

← Explore the full Protocol Vault

↑ Back to on this page